Skip to main content

Table 1 Population characteristics. Data are expressed as n (%) or median (IQR)

From: Crohn’s disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic

 

CD n = 21

UC n = 56

Gender (F)

13 (61.9%)

33 (58.9)

Age

59.1 (45.2–65.8)

56.3 (40.3–64.1)

Disease duration

6 (5–10)

7 (3–12)

Extent

 E1(proctitis and proctosigmoiditis)

 

8 (14.3%)

 E2(left sided colitis)

 

29 (51.8%)

 E3 (pancolitis)

 

17 (33.9%)

Localization

 L1 (ileal)

13 (61.9%)

 

 L2 (colic)

3 (14.3%)

 

 L3 (ileocolic)

5 (23.8%)

 

Behavior

 B1 (inflammatory)

12 (57.1%)

 

 B2 (stenotizing)

6 (28.6%)

 

 B3 (penetrating)

3 (14.3%)

 

 Biologics/ISS

9 (42.7%)

4 (7.14%)

 Surgery

6 (28.6%)

0 (0%)